PT 1: The Chart: Start with the chart as it can help tell the story and can provide entry/exit points$XERS chart looks bullish with the RSI, MACD and MFI all curling upward with a gap to fill after a very smart offering (more on the offering later) pic.twitter.com/P10rjDXkWT

— Conan the Barbarian (@BarbarianTrades) July 14, 2020

PT3: The Technology: $XERS has two technologies that make it attractive (XeriSol and XeriJect) both are non-aqueous formulations with high stability and solubility which allows for the elimination of refrigeration and significantly reduces injection volumes

— Conan the Barbarian (@BarbarianTrades) July 14, 2020

PT4: The Product: $XERS The Gvoke HypoPen just received FDA approval as the first autoinjector for Severe Hypoglycemia and is its commercial launch was on July 1. Benefits: Pre-mixed ready-to-go injector; 99% of patients used correctly, 100% proven in adults and kids

— Conan the Barbarian (@BarbarianTrades) July 14, 2020

PT5: The Launch: Why is the $XERS launch more successful than it is being perceived? The company took a parallel path approach during trials to onboard insurance providers and Medicare so that upon launch almost 80% of providers and Medicare are covered with $0 copay

— Conan the Barbarian (@BarbarianTrades) July 14, 2020

PT6 Cont: Why is this positive for $XERS? 1. Debt can be leveraged to create greater returns increasing shareholder value and equity dilution reduces shareholder value.

— Conan the Barbarian (@BarbarianTrades) July 14, 2020

PT7: The Pipeline: $XERS has a robust pipeline with numerous catalyst this year and early 2021 pic.twitter.com/SmucFXVyXx

— Conan the Barbarian (@BarbarianTrades) July 14, 2020

Enjoying profits and learned the DD game from these guys. Give them a follow @Hugh_Henne @The_Analyst_81 @KamBigStocks @yatesinvesting @MrZackMorris @bogtrading

— Conan the Barbarian (@BarbarianTrades) July 14, 2020

⬇ ⬇ ⬇ What do you think of this DD? Leave a rating below!